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Background: Allogeneic haematopoietic stem cell transplantation (allo-SCT) may provide donor cytotoxic T cell-/NK cell-mediated disease control in patients with
rhabdomyosarcoma (RMS). However, little is known about the prevalence of graft-vs-RMS effects and only a few case experiences have been reported.
Methods: We evaluated allo-SCT outcomes of 30 European Group for Blood and Marrow Transplantation (EBMT)-registered patients with advanced RMS regarding
toxicity, progression-free survival (PFS) and overall survival (OS) after allo-SCT. Twenty patients were conditioned with reduced intensity and ten with high-dose
chemotherapy. Twenty-three patients were transplanted with HLA-matched and seven with HLA-mismatched grafts. Three patients additionally received donor
lymphocyte infusions (DLIs). Median follow-up was 9 months.
Results: Three-year OS was 20% (s.e.±8%) with a median survival time of 12 months. Cumulative risk of progression was 67% (s.e.±10%) and 11% (s.e.±6%) for
death of complications. Thirteen patients developed acute graft-vs-host disease (GvHD) and five developed chronic GvHD. Eighteen patients died of disease and four
of complications. Eight patients survived in complete remission (CR) (median: 44 months). No patients with residual disease before allo-SCT were converted to CR.
Conclusion: The use of allo-SCT in patients with advanced RMS is currently experimental. In a subset of patients, it may constitute a valuable approach for
consolidating CR, but this needs to be validated in prospective trials.
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Rhabdomyosarcoma (RMS) is the most common soft-tissue
sarcoma (STS) in children and adolescents (Perez et al, 2011). As
the term RMS describes a heterogeneous family of STS,
histomorphology, tumour site, and clinical course may vary
depending on the subtype. The most prevalent subtypes are
embryonal RMS occurring in 67% and alveolar RMS occurring in
B32% of RMS patients under the age of 20 years (Perez et al,
2011). Whereas embryonal RMS may harbour a broad spectrum of
genetic aberrations, B80% of alveolar RMS are characterised by
specific chromosomal translocations causing the fusion of the
forkhead box O1 gene (FOXO1 alias FKHR) with either the paired
box gene 3 (PAX3) or the PAX7 gene [t(2;13)(q35;q14) and
t(1;13)(p36;q14)] leading to the formation of oncogenic transcrip-
tion factors (Pappo et al, 1995). Although survival rates of patients
with localised disease have considerably improved within past
decades (Pappo et al, 1995; Stevens et al, 2005), metastatic and
recurrent disease (advanced RMS) are commonly associated with
fatal outcome (Stevens, 2005).
The implementation of high-dose chemotherapy (HDC)
followed by autologous haematopoietic stem cell transplantation
(SCT) could not achieve satisfactory overall survival (OS) rates in
RMS patients (Koscielniak et al, 1997; Carli et al, 1999; Dantonello
et al, 2009; Peinemann et al, 2011). Allogeneic haematopoietic
SCT (allo-SCT) with or without the intentional infusion of
donor lymphocytes (Tomblyn and Lazarus, 2008) has improved
relapse-/progression-free survival (PFS) and OS in a growing
number of high-risk patients with other cancer entities, possibly
due to a T cell-/NK cell-mediated graft-vs-tumour effect (Childs
et al, 2000; Ueno et al, 2003; Bishop et al, 2004; Bregni et al, 2004;
Kolb et al, 2004; Lundqvist and Childs, 2005; Mackensen et al,
2006; Rizzo et al, 2009; Reisner et al, 2011). These observations
suggest that allo-SCT and cellular immunotherapy may also
improve outcome for RMS patients. However, little is known about
graft-vs-RMS effects in patients treated with allo-SCT and only few
single-centre case experiences have been reported (Misawa et al,
2003; Donker et al, 2009; Ohta et al, 2011).
In this retrospective study, we summarise the experiences drawn
from the treatment of 30 patients with advanced RMS included in
the European Group for Blood and Marrow Transplantation
(EBMT) registries. All patients were treated with experimental
allo-SCT and were not enrolled in ongoing prospective trials at the
date of data censure. We evaluated their medical records in regard
to conditioning regimens, HLA graft matching, toxicity, PFS, and
OS to define the value of allo-SCT in the treatment of patients with
advanced RMS and to discuss its potential in future immunother-
apeutic approaches.
PATIENTS AND METHODS
Study design and data provenience. We evaluated data of all 30
EBMT-registered patients with advanced RMS and treated with
allo-SCT between 1995 and 2011 (Tables 1, 2, and 3). Inclusion
criteria were diagnosis of RMS (all subtypes), allo-SCT after 1995
and non-participation in ongoing prospective trials. Diagnosis was
based on the clinical and histopathological examination. In nine
patients with alveolar RMS, diagnoses were furthermore confirmed
by molecular-genetic detection of specific chromosomal transloca-
tions. Three patients with alveolar RMS were translocation
negative, whereas the presence of alveolar RMS was analysed
merely histopathologically in 12 further patients (see also Table 2).
Date of data censuring was 30 November 2011. In the following
sections, patient numbers are followed by the indication of
respective proportions given in brackets whenever appropriate.
Definitions. Engraftment was defined as an absolute neutrophil
count ofX0.5 109 l 1 after allo-SCT. When patients died within
100 days post transplantation or when information was unavail-
able, chronic GvHD was considered as not assessable. Death of
complications (DOCs) constituted any death occurring after allo-
SCT in the absence of disease evidence including engraftment
failure. The term death of disease (DOD) defines any death directly
related to either disease progression or relapse. Progressive disease
(PD) was defined as treatment-resistant increase in tumour
volume, partial remission (PR) was defined as tumour volume
reduction and complete remission (CR) as the absence of
detectable disease. Residual disease included both PD and PR.
Relapse-free survival (RFS) was defined as the time from last allo-
SCT until the occurrence of any local or metastatic RMS evidence
in patients who had reached CR after treatment. The PFS included
RFS and was defined as the survival period after allo-SCT until date
of relapse in patients transplanted in CR, and until date of
progression diagnosis in case patients were transplanted with
residual disease. Tumours were staged according to the WHO
classification. HLA mismatch was defined as X1 known allele
mismatch in HLA class 1 and/or HLA class 2.
Statistical analyses. Data censure was conducted on 30 November
2011. Statistical analyses were performed using R 2.11.0 (The R
Foundation for Statistical Computing, Vienna, Austria) and Prism
5 software (GraphPad Software, San Diego, CA, USA). Median
survival time was defined as the time at which fractional survival
equaled 50%. Time values for PFS and OS estimates were assessed
starting on the date of the last allo-SCT until date of relapse/last
follow-up and for OS until death independent of the cause or last
follow-up. The PFS and OS probabilities were estimated using the
Kaplan–Meier method with patients alive at last follow-up
censored. Cumulative incidence curves were applied to estimate
the occurrence of relapse and DOC, with DOC being a competing
event for progression/relapse occurrence and vice versa as
described (Scrucca et al, 2007). Standard errors (s.e.) for survival
and cumulative risk estimates are given in brackets. As this is a
retrospective study of a limited number of patients with
heterogeneous clinical courses, statistical significance calculations
regarding univariate group comparisons or multivariate analyses
were not performed.
RESULTS
Patient characteristics. All patients or their guardians gave
written informed consent before therapy. Treatment relied on
institutional review board approvals according to the Declaration
of Helsinki. The study population consisted of 13 (43%) female and
17 (57%) male patients. Median age at diagnosis was 14 years
(range: 2–28 years) and 16 years at allo-SCT (range: 4–28 years).
Ten (33%) patients had received HDC and twenty (67%) patients
reduced-intensity chemotherapy (RIC) before allo-SCT. In total, 23
(77%) patients received grafts from either HLA-matched related or
matched unrelated donors, whereas 7 (23%) patients received
either haplo-identical or otherwise HLA-mismatched grafts.
Eligibility for allo-SCT was decided in case of relapse or PD after
first-line treatment. Selection of patients suitable for allo-SCT was
heterogeneous. In some of these patients, the presence of an HLA-
matched sibling positively influenced the decision. After induction
and conditioning treatment 24 patients received allografts in the
absence of detectable disease after conditioning for allo-SCT,
whereas 6 patients had residual disease after allo-SCT (Table 2). As
this is a retrospective analysis of an internationally recruited study
population, an objective side-by-side assessment by a single
reference radiologist and reference pathologists was not performed.
Graft source was bone marrow in 16 (53%) patients, peripheral
blood in 10 (33%), and cord blood in 4 (13%) patients. Nine (3%)
patients had received autologous grafts before allo-SCT. One
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patient received a second allogeneic graft due to initial graft failure.
Three patients received donor lymphocyte infusions (DLIs) after
allo-SCT. Patient characteristics are summarised in Table 1.
Conditioning regimen and GvHD prophylaxis. Reduced-
intensity chemotherapy regimens were mainly based on fludar-
abine (FLU, 150–200mgm 2) combined with the following
drugs and/or total body irradiation (TBI): melphalan (MEL,
140mgm 2; n¼ 2), intravenous busulfan (BU, 6–8mg kg 1;
n¼ 5), cyclophosphamide (CTX, 50–120mg kg 1; n¼ 1), CTX
(50mg kg 1) combined with 2Gy TBI (n¼ 4). In other patients,
RIC comprised CTX (120mg kg 1) with thiotepa (TT)
(10mg kg 1; n¼ 2), MEL (140mgm 2) combined with TT
(15mg kg 1; n¼ 5) or TT alone (TT, unknown dosage; n¼ 1).
High-dose chemotherapy comprised FLU (150mgm 2)
combined with treosulfan (TREO, 36 gm 2; n¼ 1), CTX
(120–180mg kg 1) combined with oral BU (12.8mg kg 1) and
etoposide (ETO, 30mg kg 1; n¼ 2), MEL (140mgm 2)
combined with TT (10mg kg 1) and carboplatin
(CP, 1500mgm 2; n¼ 1), CP (unknown dosage) combined with
TT (10mg kg 1) and topotecan (TOPO, unknown dosage; n¼ 1),
FLU (120mgm 2) combined with oral BU (16mg kg 1) and TT
(10mg kg 1; n¼ 1), FLU (150mgm 2) combined with MEL
(120mgm 2) and TT (10mg kg 1; n¼ 1), CTX (180mg kg 1)
combined with oral BU (16mg kg 1; N¼ 1), CTX (120mg kg 1)
combined with oral BU (16mg kg 1) and TT (10mg kg 1; n¼ 1)
and FLU (150mgm 2) combined with MEL (120mgm 2) and
TREO (36 gm 2, n¼ 1). For assessment of conditioning regimens
only the effect of the latest allo-SCT was analysed. The GvHD
prophylaxis included methotrexate, mycophenolate-mofetil,
tacrolimus, cyclosporine A, and/or prednisolone. At least one
patient received OKT3 and at least seven patients received
polyclonal anti-thymocyte globulins. Individual regimens are
provided in Table 2.
Engraftment rates and GvHD. Twenty-seven (90%) patients
engrafted successfully whereas three (10%) patients (patients #11,
#20, and #24; Table 2) initially failed to engraft of whom one
patient received a second allogeneic graft (patient #24; Table 2).
Acute and chronic GvHD were defined in accordance with the
ICD-10 system proposed by the WHO. Overall acute GvHD was
reported in 13 (43%) patients. In 6 (20%) patients, chronic GvHD
was not assessable due to either deathor last FU before day 100
after allo-SCT. Overall chronic GvHD occurred in 5 of 24 (21%)
patients.
Table 1. Patient and treatment characteristics
RMS patients (n¼30)
Number Fraction
Age at diagnosis (years)
0–9 8 0.27
10–19 19 0.63
20–29 3 0.10
Gender
Male 17 0.57
Female 13 0.43
Date of diagnosis
o2000 4 0.13
X2000 26 0.87
Date of last allo-SCT
o2000 1 0.03
X2000 29 0.97
RMS subtype
Alveolar 23 0.77
Embryonal 3 0.10
Unknown 4 0.13
First-line local treatment modality
Surgery only 5 0.17
Irradiation only 9 0.30
Surgeryþ Irradiation 9 0.30
None 5 0.17
Unknown 2 0.07
Stage at diagnosis
Stage II at Diagnosis 1 0.03
Stage III at Diagnosis 3 0.10
Stage IV at Diagnosis 23 0.77
Unknown 3 0.10
Status at allo-SCT
CR 24 0.80
Residual disease 6 0.20
Previous graft
No previous graft 20 0.67
Allogeneic graft once 1 0.03
Autologous graft(s) 9 0.30
Transplant conditioning regimen
RIC 20 0.67
HDC 10 0.33
Total body irradiation
Yes (all 2 Gy) 4 0.13
No 26 0.87
Graft source for allo-SCT
BM 16 0.53
PB 10 0.33
CB 4 0.13
Table 1. ( Continued )
RMS patients (n¼30)
Number Fraction
Donor HLA match
Matched related 17 0.57
Matched unrelated 6 0.20
Mismatcheda 7 0.23
DLI after allo-SCT
Yes 3 0.10
No 26 0.87
Unknown 1 0.03
Abbreviations: allo-SCT¼ allogeneic stem cell transplantation; BM¼bone marrow;
CB¼ cord blood; CR¼ complete remission; DLIs¼donor lymphocyte infusions;
HDC¼ high-dose chemotherapy; PB¼peripheral blood; PD¼progressive disease;
PR¼partial remission; RIC¼ reduced-intensity chemotherapy; RMS¼ rhabdomyosarcoma.
aX1 allele mismatch in HLA class 1 and/or HLA class 2.
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Within patients treated with HLA-matched grafts, 10 of 23
(43%) patients developed acute GvHD (I–II, n¼ 4; III–IV, n¼ 5;
unavailable information in one patient). In the same group, 4 of 23
(17%) patients developed limited (n¼ 3) or extensive (n¼ 1)
chronic GvHD, whereas status information remained unavailable
in 4 of 23 patients due to early death or last follow-up before day
100 after allo-SCT. Within patients treated with mismatched grafts,
3 of 7 patients (43%) developed acute GvHD (I–II, n¼ 2; III–IV,
n¼ 1), 1 of 7 (14%) patients developed extensive chronic GvHD
and no patient developed limited chronic GvHD, whereas status
information remained unavailable in 2 of 7 patients due to early
death or last follow-up before day 100 after allo-SCT (Table 3).
Within patients treated with RIC as conditioning regimen for
allo-SCT, 11 of 20 (55%) patients developed acute GvHD (I–II,
n¼ 5; III–IV, n¼ 6). In the same group, 1 of 20 (5%) patients
developed limited and no patient developed extensive chronic
GvHD, whereas status information remained unavailable in 4 of 20
patients due to early death or last follow-up before day 100 after
allo-SCT. Within patients treated with HDC as conditioning
regimen for allo-SCT, 2 of 10 patients (20%) developed acute
GvHD (III–IV, n¼ 1; unavailable grade information in one
patient), whereas 4 of 10 (40%) patients developed limited
(n¼ 2) chronic GvHD or extensive (n¼ 2) chronic GvHD. Status
information remained unavailable in 2 of 10 patients due to early
death or last follow-up before day 100 after allo-SCT. In the whole
group, one patient died due to GvHD (IV). Data summaries are
given in Tables 2 and 3.
Overall survival. At the time of data censure, 22 of 30 (73%)
patients had died due to disease or due to treatment-related
complications and 8 of 30 (27%) patients were alive in CR (median:
44 months; range: 2–119 months). In all, 6 of 30 patients did
not reach CR after allo-SCT. Median follow-up was 9 months
(range: 1–119 months). Median survival time was 12 months. The
OS estimate at day 100 after allo-SCT was 83% (s.e.±7%) and the
3-year OS estimate was 0.20 (s.e.±8%) (Figure 1). Survival data
are summarised in Tables 2 and 3.
Progression-free survival. In total, 24 of 30 patients (80%) were
in CR before allo-SCT, but none were converted from residual
disease into CR. At data censure, 13 of 24 patients (54%) had
relapsed, 3 (13%) patients had died due to complications in CR and
8 (33%) patients survived in CR (see above). One patient (patient
#5; Table 2) died due to treatment-related complications after
having relapsed. Median follow-up was 6 months (range: 1–119
months). The cumulative risk of disease progression including
relapse for these patients was 34% (s.e.±9%) at day 100 and
67 (s.e.±10%) at 3 years after allo-SCT (Figure 2A). Results are
summarised in Table 2.
Death of complications. In all, 4 of 30 (13%) patients died due to
treatment-related complications. The cumulative risk for DOC at
day 100 after allo-SCT was 7% (s.e.±5%) and 11% (s.e.±6%) at 3
years after allo-SCT (Figure 2B). Reasons causing DOC were
infection (n¼ 2), veno-occlusive disease (n¼ 1) and IV GvHD
(n¼ 1) (Tables 2 and 3).
Survival after reduced and high-dose chemotherapy. At data
censuring, 1 of 20 (5%) patients treated with RIC had died due to
treatment-related complications, 10 (50%) had relapsed and died,
4 (20%) had not reached CR and died and 5 (25%) patients
Table 3. Group results: HDC vs RIC and HLA-matched vs HLA-mismatched allo-SCT
RIC (n¼20) Myeloablative (n¼10) HLA matched (n¼23) HLA mismatcheda (n¼7)
Parameter Number Fraction Number Fraction Number Fraction Number Fraction
Engraftment
Success 19 0.95 10 1.00 23 1.0 6 0.86
Failure 1 0.05 0 0.00 0 0.00 1 0.14
Acute GvHD
None 9 0.45 8 0.80 13 0.57 4 0.57
Grades I–II 5 0.25 0 0.00 4 0.17 2 0.29
Grades III–IV 6 0.30 1 0.10 5 0.22 1 0.14
aGvHD but WHO unavailable 0 0.00 1 0.10 1 0.04 0 0.00
Chronic GvHD
None 15 0.75 4 0.40 15 0.65 4 0.57
Limited 1 0.05 2 0.20 3 0.13 0 0.00
Extensive 0 0.00 2 0.20 1 0.04 1 0.14
N.a. due to death or last FU p d100 4 0.20 2 0.20 4 0.17 2 0.29
Outcome
DOC 1 0.05 3b 0.30 4b 0.17 0 0.00
Relapse/DOD 14 0.70 5b 0.50 13b 0.57 6 0.86
Alive in CR at last FU 5 0.25 3 0.30 7 0.30 1 0.14
Median FU (months after allo-SCT)
Median 8 12 12 5
Range 1–62 2–119 1–119 2–62
Abbreviations: DOC¼death of complications; DOD¼death of disease; FU¼ follow-up; GvHD¼graft-vs-host disease; HDC¼ high-dose chemotherapy; RIC¼ reduced-intensity chemotherapy.
aX1 allele mismatch in HLA class 1 and/or HLA class 2.
bOne patient had relapsed before death of complications.
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were surviving in CR. Median follow-up in RIC-treated patients
was 8 months (range: 1–62 months).
Of 10 patients treated with HDC-based conditioning 3 (33%)
had died due to treatment-related complications, 3 patients (33%)
relapsed (of whom 1 died of complications after relapse and was
thus classified as both relapsed and DOC), 2 patients (20%) had
not reached CR and died and 3 (33%) patients survived in CR.
Median follow-up in HDC-treated patients was 12 months (range:
2–119 months). Results are summarised in Tables 2 and 3.
Survival with HLA-mismatched and HLA-matched grafts. Of 23
patients treated with HLA-matched grafts, 4 (17%) patients had
succumbed due to treatment-related complications, 8 (35%)
patients had relapsed and died, 5 (22%) patients had not reached
CR and died and 7 (33%) patients had survived in CR. Median
follow-up in patients treated with HLA-matched grafts was
12 months (range: 1–119 months) (Tables 2 and 3). Of 7 patients
who received HLA-mismatched grafts, no one succumbed to
treatment-related complications, 5 (71%) relapsed and died,
1 (14%) had not reached CR and died and 1 (14%) survived in
CR. Median follow-up in patients treated with HLA-mismatched
grafts was 5 months (range: 2–62 months) (Tables 2 and 3).
DLIs and GvHD. Three out of thirty patients received DLIs after
allo-SCT (patients #4, #9, and #19; Table 2). Patient #4 was PR
when she received two doses of 1 107 CD3-positive donor
lymphocytes per kilogram body weight upfront without prepara-
tive chemo- or radiotherapy. She did not develop GvHD after DLI.
Three weeks post DLI she showed tumour progression. Patient #9
relapsed after allo-SCT and received seven doses of donor
lymphocytes in escalating doses (1, 3, 5, 10, 25, 50,
and 100 106 CD3-positive cells per kg body weight) in
combination with IL2 administration between DLI numbers 5
and 6 (at a total dose of 25 million units). Pretreatment before DLI
consisted of surgical resection and chemotherapy (CWS 96 relapse
protocol). The patient did not develop GvHD after DLI and was in
CR for 97 months at the time of data censure. Patient #19 had
relapsed PD after allo-SCT and received a single dose of 1 108
CD3-positive cells per kg body weight without preparative
chemotherapy. Pretreatment consisted of radiotherapy of the
relapse site. After DLI she did not develop GvHD but showed
tumour progression. Altogether, despite high doses of donor
lymphocytes none of these three patients developed GvHD
after DLI.
DISCUSSION
The rationale for treating cancer patients with allogeneic grafts is a
hypothesised graft-vs-tumour effect of donor-derived cytotoxic T
cells and/or natural killer cells that may unavoidably be given
during infusion of haematopoietic stem cells for immune
reconstitution or intentionally thereafter as DLI (Childs et al,
2000; Ueno et al, 2003; Bishop et al, 2004; Bregni et al, 2004; Kolb
et al, 2004; Lundqvist and Childs, 2005; Mackensen et al, 2006;
Rizzo et al, 2009; Reisner et al, 2011). Little is known about graft-
vs-RMS effects in patients treated with allo-SCT and only few
single-centre case experiences have been reported (Misawa et al,
2003; Donker et al, 2009; Ohta et al, 2011). In this study, we
evaluated individual therapy outcomes of 30 patients with
advanced RMS of all subtypes who became eligible for experi-
mental allo-SCT. We focussed on toxicity, OS, PFS, and the
possible presence of a graft-vs-RMS effect. As this is a retrospective
study of a limited cohort with heterogeneous clinical courses, we
did not carry out statistical significance calculations in regard to
univariate group comparisons or multivariate analyses.
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Figure 1. Overall survival probability in the study group (n¼ 30) from
the date of allo-SCT; patients #3, #9, #10, #15, #21, #23, #24, and #28
were alive at last follow-up were censored. Abbreviation: Allo-SCT,
allogeneic stem cell transplantation.
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Figure 2. (A) Cumulative risk analysis for progression of study group
patients (n¼ 30) after allo-SCT; patients #3, #9, #10, #15, #21,
#23, #24, and #28 were alive at last follow-up were censored.
(B) Cumulative risk analysis for treatment-related mortality in the
study group (n¼30) after allo-SCT; patients #3, #9, #10, #15, #21,
#23, #24, and #28 were alive at last follow-up were censored.
Abbreviations: DOC, death of complications; allo-SCT, allogeneic stem
cell transplantation.
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With a probability of 20%, 3-year OS in RMS patients treated
with allo-SCT was comparable to the results of a recent meta-
analysis reporting on the efficacy of HDC combined with
autologous haematopoietic SCT in patients with advanced RMS
(Peinemann et al, 2011). It has to be considered though, that
survival data of four patients were censored within the 3 years
following allo-SCT. In our analysis, with an overall DOC rate of
13%, toxicity seems to be controllable but yet not satisfactory. As
death may be a competing event for toxicity onset, GvHD rates
described here need to be interpreted with caution due to varying
observation periods. An evaluation of possibly shared features of
long-term survivors (here defined as CR for 42 years after allo-
SCT) that could have led to cure remains elusive within our cohort.
Similarly, a specific evaluation of the possible contribution of the
donor’s immune system for RMS control is not feasible because
patients had received multimodal therapies. Six patients were
transplanted with residual disease. Of these patients, five patients
were diagnosed with PD within 4 months after allo-SCT and one
patient progressed 10 months after allo-SCT. All of these patients
died of disease. However, it should be noted that a number of
patients showed remarkable long PFS and/or OS after allo-SCT
(Table 2). Four of five patients (#1, 2, 5, and 19) had chronic
GvHD and survived for X12 months after allo-SCT. Of these
patients, patient #1 was transplanted without reaching CR and
survived with stable disease for 10 months. The most impressive
clinical course was seen in patient #9 (stage IV eRMS, disseminated
and chemo-resistant disease after first-line treatment) who relapsed
28 months after transplantation, received seven times DLI
thereupon, reached CR after surgery and chemotherapy with
escalating DLI treatment and was surviving in CR for 97 months at
the date of last follow-up. However, CR may have been due to
surgery and chemotherapy rather than DLI. Again, it is
not possible to precisely measure the role of infused T cells
in this patient.
Several studies on the immunotherapeutical role of allo-SCT in
patients with solid tumours and lympho-/myeloproliferative
diseases could reveal or at least indicate the presence of a GvTE
(Childs et al, 2000; Ueno et al, 2003; Bishop et al, 2004; Bregni et al,
2004; Kolb et al, 2004; Koscielniak et al, 2005; Lundqvist and
Childs, 2005; Mackensen et al, 2006; Rizzo et al, 2009; Reisner et al,
2011). However, it remains unclear under which precise
constellations this effect may become clinically relevant and if this
effect is strong enough to outweigh the risk of severe GvHD.
Recent progress in drug development for the control of severe
GvHD has facilitated the flexibility on donor choice, that is, it has
become possible to use grafts that were not fully HLA compatible
(Reisner et al, 2011; Thiel et al, 2011b; Wernicke et al, 2011).
Despite this, HLA-mismatched grafts remain associated with a
higher risk of GvHD, but may yield higher graft-vs-tumour
responses in a small spectrum of cancer entities (Reisner et al,
2011). The observation that a transplanted immune system may be
able to control tumour progression or even cure patients, but on
the other hand can cause life-threatening toxicity (Wernicke et al,
2011) has led to the development and the implementation of
immunotherapeutical approaches using cancer/testis antigen
selective cytotoxic T cells (Dalerba et al, 2001; Kuci et al, 2010)
or NK cells (Lang et al, 2006; Perez-Martinez et al, 2009), either in
an autologous (Morgan et al, 2006; Dudley et al, 2008) or in an
allogeneic setting (Thiel et al, 2011a). Especially, the generation of
T-cell receptor transgenic (Spranger et al, 2012) and/or chimaeric
antigen receptor (CAR) (Marcus et al, 2011; Pegram et al, 2012)
modified T cells against cancer/testis antigens appear to be a
promising tool to facilitate specific anti-tumour responses.
The use of HDC regimens may elicit protective effects
concerning disease relapse after autologous/allo-SCT in some
paediatric sarcoma patients, but is bought with increased toxicity
(Burdach et al, 2000). In contrast, RIC-based conditioning before
allo-SCT for Ewing sarcomas was intended to facilitate a possible
graft-vs-tumour effect, but was associated high relapse rates
(Thiel et al, 2011b). The question which conditioning regimen is
preferable has to be adressed in controlled prospective trials.
For patients with advanced paediatric sarcomas, it seems as if
the different conventional conditioning approaches have reached a
plateau considering rates of cure (Carli et al, 2004; Thiel et al,
2011b). Moreover, despite the presence of higher but improvingly
controllable toxicity, it has to be questioned whether allo-SCT
should be merely regarded upon as an experimental option to cure
disease by itself. Allogeneic responses of donor T cells against non-
self antigens may cause potent tissue rejection as seen in patients
developing GvHD after allo-SCT, whereas autologous T cells may
have developed central and peripheral tolerance to self-tissue
including tumour tissue. Allogeneic T cells are not subjected to
central tolerance and may overcome peripheral tolerance upon
transfer if respective immunomodulatory pre- and post transplan-
tation regimens are implemented. In this context, several
immunomodulatory regimens for DLI, for example, lymphodeple-
tion (Gattinoni et al, 2005), specific regulatory T cells depleting
chemotherapy (Zhao et al, 2010), hyperthermia of tumour sites
(Jolesch et al, 2012), blockade of immune checkpoint proteins (e.g.,
CTLA-4 and PD-1; Weber, 2010) and specific dendritic cell-based
tumour vaccines (Ueno et al, 2010) have been proposed to enhance
efficacy of immunotherapy. Furthermore, in sarcoma patients
relapsing after allo-SCT an effect of increased chemosensitivity was
recently reported, an observation that emphasises the need to
explore the role of post-transplant chemotherapy regimens (Baird
et al, 2012). The efficacy of each approach may be potentiated
using individually tailored immunotherapeutic protocols combined
with rescue chemotherapy and additional targeted therapy
of crucial oncogenic pathways in tumour cells (Grunewald et al,
2012). Allo-SCT may therefore serve as a platform for additional
immunotherapeutic approaches using, for example, (specific) DLI.
It is still unclear how patients shall be conditioned to facilitate and/
or enable curative immunotherapeutic effects. In our analysis, 3 out
of 30 patients received high doses of DLI for relapse treatment after
allo-SCT. Two of these patients received upfront high doses of DLI
without prior dose escalation but did not develop GvHD
afterwards. This observation hints at the presence of a possibly
tumour mediated immune evasion (Mapara and Sykes, 2004).
With an OS probability of 20%, allo-SCT seems to be a feasible
therapy option for patients with advanced RMS. Furthermore, the
study population was heterogeneous in regard to patient and
disease characteristics, previous treatments/outcomes of these
treatments, reasons for allo-SCT, conditioning regimens, and
observation periods. Therefore, the results have to be interpreted
with caution. However, despite the limitations associated with all
retrospective studies, we provide a systematic description of
individual outcomes of a relatively large number of RMS patients
treated with allo-SCT. Allo-SCT may constitute a suitable platform
for immunotherapeutic approaches using, for example, (antigen-
specific) DLI in the treatment of RMS patients with advanced
disease in a multimodal setting comprising novel therapy
approaches (Wan et al, 2006; Crose et al, 2012; Fulda, 2012). But
the question under which circumstances it may be justified may
only be answered in controlled clinical trials with prospective data
collection.
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